Crossmark

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy

Crossref DOI link: https://doi.org/10.1007/s00277-018-3509-0

Published Online: 2018-10-18

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alkharabsheh, Omar A.

Saadeh, Salwa S.

Zblewski, Darci L.

Gangat, Naseema

Begna, Kebede H.

Elliott, Michelle A.

Alkhateeb, Hassan B.

Patnaik, Mrinal S.

Hogan, William J.

Litzow, Mark R.

Al-Kali, Aref
License Information

Text and Data Mining valid from 2018-10-18
More Information

Article History

Received: 25 July 2018

Accepted: 2 October 2018

First Online: 18 October 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: This is a retrospective study, approved by the Mayo Clinic IRB; informed consent was obtained from all individual participants included in the study.